Join us for a symposium bringing together leading experts who will unveil concepts, approaches, and technologies for drug design that could transform the future of pharma, critically analyzing the opportunities and challenges toward widespread adoption.
Artificial intelligence seems to be everywhere, with applications in almost all fields of modern science. From robotics and biology to chemical engineering and healthcare, excitement surrounds the potential of AI to further digital healthcare. How might we define “intelligent behavior” in the context of drug discovery?
Recent advances in adaptive robotic systems, automated chemical syntheses, and biological testing, as well as AI systems, are poised to improve the design process for tomorrow’s drugs. However, such approaches raise considerable conceptual, technical, and organizational challenges within a storm of hype and skepticism. We will evaluate the feasibility of fully autonomous molecular design with the aid of computers and robotic devices, to determine which tasks are suited to a chemically savvy artificial intelligence, and which should remain in the domain of the skilled human mind.
6:00pm — doors open
6:30pm — content starts
8:00pm — networking
9:30pm — doors close
Chris Luebkeman’s interest in the built environment propelling him to pursue a multi-faceted education, beginning with engineering and culminating in a Doctorate in Architecture from ETH in Zurich, a city to which he remains deeply connected. Chris gained valuable experience as the protégé of esteemed Spanish Architect, Santiago Calatrava. He subsequently turned to his other love, education, by accepting teaching positions at several prestigious universities. In 1999, Chris joined Arup as the co-Director for Research and Development. A couple of years later, he formed the Foresight, Innovation and Incubation team, which has evolved into its present form as Research + Foresight + Innovation.
Gisbert Schneider is a full professor at ETH Zurich, holding the Chair for Computer-Assisted Drug Design, and the Associate Vice President for ETH Global. He received his PhD in Biochemistry from Freie Universität Berlin. He then joined Roche Pharma in Basel as a cheminformatics group leader. From 2002 to 2009, he was a full professor at Goethe-University in Frankfurt (Beilstein Endowed Chair). His research focuses on the integration of artificial intelligence into practical medicinal chemistry.
Since Jan. 2018, Jennifer Listgarten is a Professor in the Department of Electrical Engineering and Computer Science, and Center for Computational Biology, at the University of California, Berkeley. She is also a member of the steering committee for the Berkeley AI Research (BAIR) Lab, and a Chan Zuckerberg investigator. From 2007 to 2017 she was at Microsoft Research, through Cambridge, MA, Los Angeles, and Redmond, WA. Before that, she completed her PhD in the machine learning group at the University of Toronto after an undergraduate degree in Physics from Queen's University in Kingston, Ontario. Jennifer's research interests are broadly at the intersection of machine learning, applied statistics, and molecular biology.
Norman Sieroka is the managing director of the Turing Centre Zurich and belongs to the core team of ETH's critical thinking initiative. He studied philosophy, physics, and mathematics in Heidelberg and Cambridge and received doctorates in both physics and philosophy. Norman Sieroka held positions as a guest professor at the Universities of Notre Dame (U.S.) and Bremen. His research focuses on conceptual questions regarding the exact sciences, the mind, and time.
Robert Goodnow completed his BS in chemistry at Georgetown University followed by a Ph.D. in natural products organic/ bioorganic chemistry at Columbia University. He continued research in oligosaccharide synthesis at Princeton University as an NIH Postdoctoral Fellow. Rob began his industrial career at Hoffmann-La Roche. In addition to many medicinal chemistry project leadership responsibilities, Rob has managed multiple outsourcing collaborations for pre-clinical discovery chemistry on a local and global level, eventually becoming the Global Leader of Medicinal Chemistry Outsourcing. Rob’s research has also focused on the implementation of several chemistry platform technologies. These include small molecule targeted delivery of siRNA for therapeutic applications, analytical chemistry and DNA-encoded chemistry. Rob’s efforts in medicinal chemistry have been focused on projects in oncology, inflammation and metabolic diseases. He has authored or co-authored more than 80 scientific papers, book chapters and patent applications. He edited a book entitled “A Handbook of DNA-Encoded Chemistry”; recently he edited Annual Reports in Medicinal Chemistry Vol. 50. In 2013, Rob joined AstraZeneca as the Executive Director of the Discovery Sciences Chemistry Innovation Centre leading efforts in chemical biology, fragment-based lead generation and computational chemistry. Rob joined Pharmaron as Vice President Innovation Chemistry in October 2016 responsible for shared risk research programs.
Additional speakers to be announced.